Haiying Zhou
About Haiying Zhou
Haiying Zhou is the Director of Clinical Biomarker, Translational Science at Arcus Biosciences, with extensive experience in translational medicine and oncology. Previously, Zhou held various roles at Zai Lab, ORIC Pharmaceuticals, and Exelixis, contributing to multiple oncology projects and regulatory filings.
Current Role at Arcus Biosciences
Haiying Zhou serves as the Director of Clinical Biomarker, Translational Science at Arcus Biosciences. He has held this position since 2023, working in Hayward, California. In this role, Zhou focuses on the integration of clinical biomarkers into translational science, contributing to the development of innovative oncology therapies.
Previous Experience at Zai Lab
Prior to his current role, Zhou worked at Zai Lab as Director of Translational Medicine, Immuno-oncology for six months in 2022. He also served as Associate Director of Translational Medicine from 2020 to 2022. During his time at Zai Lab, he was involved in advancing oncology projects and enhancing the company's translational capabilities.
Background in Translational Medicine
Zhou has extensive experience in translational medicine, having worked at ORIC Pharmaceuticals in various roles from 2014 to 2020. His positions included Scientist, Oncology Discovery, Senior Scientist, and Principal Scientist. He contributed to multiple oncology projects, advancing them from preclinical stages to clinical trials.
Education and Expertise
Zhou holds a Doctor of Philosophy (PhD) in Molecular Medicine from the Graduate School of Biomedical Sciences at The University of Texas Health Science Center San Antonio. He also completed postdoctoral training at the University of California, Berkeley, where he studied Biology. His undergraduate degree is a Bachelor of Science in Chemistry from Nankai University.
Contributions to Biotechnology
Zhou has played a significant role in fundraising efforts for a biotech startup, leading to its initial public offering (IPO). He has experience managing collaborations with external contract research organizations (CROs) and leading cross-functional teams. His work includes active participation in regulatory filings such as IND submissions and clinical protocols.